Fraccarollo, Daniela

Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. [electronic resource] - Basic research in cardiology Jul 2014 - 421 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1435-1803

10.1007/s00395-014-0421-1 doi


Angiotensin-Converting Enzyme Inhibitors--pharmacology
Animals
Cardiotonic Agents--pharmacology
Cell Communication
Cells, Cultured
Disease Models, Animal
Drug Therapy, Combination
Enzyme Activation
Enzyme Activators--pharmacology
Extracellular Matrix--metabolism
Fibrosis
Guanylate Cyclase--metabolism
Heart Failure--drug therapy
Hemodynamics--drug effects
Humans
Male
Mice
Mitochondria, Heart--drug effects
Myocardial Contraction--drug effects
Myocardial Infarction--complications
Myocytes, Cardiac--drug effects
Myofibroblasts--drug effects
Nitric Oxide--metabolism
Nitric Oxide Synthase Type III--metabolism
Oxidative Stress--drug effects
Ramipril--pharmacology
Rats, Wistar
Receptors, Cytoplasmic and Nuclear--metabolism
Soluble Guanylyl Cyclase
Sulfonamides--pharmacology
Superoxides--metabolism
Time Factors
Ventricular Function, Left--drug effects
Ventricular Remodeling--drug effects
ortho-Aminobenzoates--pharmacology